2020 | 20192018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003



Highlights 2011

Emergence of four cases of KPC-2 and KPC-3-carrying Klebsiella pneumoniae introduced to Switzerland, 2009-10I

This paper describes four cases of patients suffering from severe infections caused by highly resistant germs introduced from foreign countries and shows how very limited treatment options are. Babouee B, Widmer AF, Dubuis O, Ciardo D, Droz S, Betsch BY, Garzoni C, Führer U, Battegay M, Frei R, Goldenberger D. Euro Surveill. 2011 Mar 17;16(11). pii: 19817


Bioavailability of extended-release nevirapine 400 and 300 mg in HIV-1: a multicenter, open-label study

Nevirapine is a widely used drug in HIV-therapy. In this study a once-daily administered formula was investigated in respect to biodiversity. This study is an FDA registry study and is required for the following important phase III-studies. Battegay M, Arasteh K, Plettenberg A, Bogner JR, Livrozet JM, Witt MD, Mossdorf E, Yong CL, Zhang W, Macha S, Berger F, Stern J, Robinson P, Quinson AM. Clin Ther. 2011 Sep;33(9):1308-20, Epub 2011 Aug 27.


Ageing with HIV: medication use and risk for potential drug-drug interactions

In this study drug-drug interactions were investigated in HIV-patients aged >50. The results show that with increasing age and comorbidities drug-drug interactions are becoming more and more important. Marzolini C, Back D, Weber R, Furrer H, Cavassini M, Calmy A, Vernazza P, Bernasconi E, Khoo S, Battegay M, Elzi L; Swiss HIV Cohort Study Members. J Antimicrob Chemother. 2011 Sep; 66(9):2107-11, Epub 2011 Jun 16.